The Penn Memory Center (PMC) is offering a variety of free programs for people living with dementia, caregivers, and their loved ones. Scroll down to browse our selection of programs and sign up to attend.
Latest News
PMC’s clinical fellow climbs to new heights
By Meghan McCarthy

Matt Van Dongen
Since childhood, Matt Van Dongen, MD, has approached life as a climb. Whether adventuring through backyard woods or navigating patient care as a physician, he depends on his passion and curiosity.
He takes that perspective into his current role, as Penn Memory Center (PMC) clinical fellow.
Dr. Van Dongen grew up in rural West Virginia, with nature as his playground.
“There wasn’t a lot going on,” he said. “I kept myself busy because we lived right up against the woods. I think I naturally climbed onto whatever I could as I kid.”
STAR program trains young scholars in aging research

Kezia Odamtten, CrystalJade Johnson, Devin Davison, Aisha Johnson, Kahina Dostaly, Jamila Zablah
By Jake Johnson
The Penn Memory Center (PMC) recently completed the third year of its Summer Training in Aging Research (STAR) program. This year marked a particular success for the program, as the number of applicants PMC received more than doubled from 2022.
As with previous years, PMC chose just six applicants to participate in the 9-week program, pairing them with mentors in the field of aging research. The STAR internship offers a valuable opportunity for students to get hands-on experience in their area of interest.
The STAR program emphasizes diversity and inclusion in the field of aging research through its application process. All undergraduate and graduate students are invited to apply to the STAR internship, but the program highly encourages students from underrepresented groups to apply.
Clark Scholar to dedicate prestigious fellowship to the fight against AD inequities

Victor Ekuta
By Meghan McCarthy
Penn Memory Center (PMC) Clark Scholar Victor Ekuta, MD, has recently been selected as a postdoctoral fellow scholar for the ANDI Health Equity Scholars Program (HESP).
The prestigious program offers training, mentorship, and a generous research stipend to support developing physicians and scientists in the field of Alzheimer’s disease (AD).
“I’m extremely humbled and honored to be selected for HESP,” said Dr. Ekuta. “I know that this award will be an important steppingstone toward becoming a culturally competent Alzheimer’s Disease physician-scientist ready to join the fight against Alzheimer’s disease inequities.”
Penn experts in neurodegenerative diseases at ANA’s 148th Annual Meeting
University of Pennsylvania clinicians and researchers who specialize in neurodegenerative diseases had a substantial presence at this year’s American Neurological Association (ANA) Annual Meeting, which took place September 9-12, in Philadelphia, PA.
Roy Hamilton, MD, MS, FANA, professor and vice chair for Inclusion and Diversity in the Department of Neurology at the University of Pennsylvania, received the Audrey S. Penn Lectureship Award for his work promoting health equity in the field of neurology.
Three UPenn researchers, Defne Amado, MD, PhD; George Kannarkat, MD, PhD; and Daniel T Ohm, PhD; were recognized as ANA Emerging Scholar Speakers, early-career researchers who are conducting cutting-edge science.
Genetic links to differences found in brain structures of patients with AD/MCI
By Meghan McCarthy
The brain is akin to a home. Genetics are the foundation. They determine the layout and style. And when there are changes in foundation, this layout shifts. Alzheimer’s disease and related dementias (ADRDs) can change the brain’s structure.
Junhao Wen, PhD, a postdoctoral researcher in the Artificial intelligence in Biomedical Imaging Lab (AIBIL) and Center for Biomedical Image Computing & Analytics (CBICA), aims to understand these changes using artificial intelligence (AI) and genetic analyses.
Last year, Dr. Wen was amongst a team of researchers who used artificial intelligence (AI) to analyze magnetic imaging resonance (MRI) scans in patients with Alzheimer’s disease (AD) or mild cognitive impairment (MCI). The team found differences the brain structures of this patient population in comparison to healthy adults.
This concept is known as neuroanatomical heterogeneity.
An Instrument Heard Round the World

How the Assessment of Capacity for Everyday Decision-making, or ACED, launched a revolution in the elder care
By Meghan McCarthy
August 2023
Seventeen years ago, on a visiting lectureship to the Geriatrics Division at Yale University, Jason Karlawish, MD, was approached by James Lai, MD. The young physician-in-training wondered if Dr. Karlawish would be open to collaborating on a research idea. Could we develop a measure of a person’s capacity to solve everyday problems?
Dr. Karlawish replied with a resounding “yes,” quickly embracing the role of mentor.
Looking back, he summed up the decision he faced: “This was in the days before Zoom and texting and such, and James was junior and working far away at a different institution. Together, that presented challenges. He couldn’t just stop into my office with a question. But never mind that, I decided. James’ timing was auspicious. I was deeply engaged in research to develop and validate instruments that assess decisional capacity.”
They set to work.
Meet PMC’s new class of Clark Scholars
By Meghan McCarthy
This year, the Christopher Clark M. Scholar program at the Penn Memory Center (PMC) welcomes four new innovative researchers.
Christopher M. Clark, MD, was a pioneer in the world of Alzheimer’s disease (AD) research and care. After accepting a faculty appointment in the Department of Neurology at the University of Pennsylvania in 1990, Dr. Clark led the Clinical Core of the Alzheimer Disease Center (ADC). He also served as a founding member of the PMC, which he directed.
In 2020, PMC’s scholars program was renamed to honor Dr. Clark and his legacy at Penn and in the field of dementia research.
Previous Clark Scholars have addressed topics of health equity, biotechnology, stigma, and biomarker research, amongst many focuses and gone on to win awards for work in supported decision making, leadership in palliative care, and exceptional contributions to the field.
PMC is excited to welcome another talented group of physicians and researchers into the program.
Diverse genetic ancestry in genomic studies illuminates new genetic risk factors for late-onset Alzheimer’s disease
By Meg McCarthy
You run several manufacturing plants for an automaker when you start getting reports of unexpected breakdowns in your new production model. You painstakingly investigate the cause of the breakdown on a part-by-part basis at one of your factories and find the problem part. You look at cars from your other factories experiencing the breakdowns but find the same part working well in those cars. What do you do?
This captures the challenge faced by the investigators of the Alzheimer’s Disease Genetics Consortium (ADGC), whose work to identify genetic risk factors for Alzheimer’s disease (AD) is complicated by the fact that the genetic variants causing disease in persons of one ancestral background may be very different from those driving disease on other background.
In research co-led by Adam Naj, PhD, a genetic epidemiologist and assistant professor of epidemiology at the University of Pennsylvania’s Perelman School of Medicine, including subjects with diverse ancestries was essential to detecting signals that would otherwise go unseen.
PMC co-directors give update on anti-amyloid therapies for Alzheimer’s at community discussion
At a virtual community event, Penn Memory Center (PMC) Co-Directors David Wolk, MD, and Jason Karlawish, MD, provided patients and families with an update on anti-amyloid treatments for Alzheimer’s disease and the plans for accessing these drugs through Penn Medicine.
Drs. Wolk and Karlawish reviewed the risks and benefits Leqembi (lecanemab), which recently received full approval from the Food and Drug Administration (FDA), and donanemab, a drug similar to lecanemab that is expected to get FDA approval at the end of 2023.
The co-directors said Penn Medicine and PMC have developed a workflow to rollout Leqembi and future drugs to PMC patients. This workflow will be piloted before becoming more widely available to patients.
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 91
- Next Page »